• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

    3/14/24 9:06:15 AM ET
    $ANNX
    $APM
    $BGXX
    $BPTS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANNX alert in real time by email

    Gainers

    • Aptorum Gr (NASDAQ:APM) shares moved upwards by 47.1% to $6.37 during Thursday's pre-market session. The company's market cap stands at $33.0 million.
    • Nuvectis Pharma (NASDAQ:NVCT) stock moved upwards by 23.65% to $11.92. The company's market cap stands at $211.8 million.
    • Bright Green (NASDAQ:BGXX) stock moved upwards by 20.99% to $0.34. The market value of their outstanding shares is at $62.5 million.
    • Unicycive Therapeutics (NASDAQ:UNCY) shares rose 14.38% to $1.59. The market value of their outstanding shares is at $55.2 million.
    • Telomir Pharmaceuticals (NASDAQ:TELO) shares rose 13.57% to $8.2. The company's market cap stands at $251.0 million.
    • Annexon (NASDAQ:ANNX) stock moved upwards by 13.34% to $6.54. The company's market cap stands at $511.9 million.

    Losers

    • Spruce Biosciences (NASDAQ:SPRB) shares fell 78.0% to $1.14 during Thursday's pre-market session. The company's market cap stands at $46.4 million. As per the news, the Q4 earnings report came out yesterday.
    • Kintara Therapeutics (NASDAQ:KTRA) stock decreased by 15.65% to $0.1. The company's market cap stands at $4.0 million.
    • Nuvation Bio (NYSE:NUVB) stock decreased by 12.04% to $2.12. The market value of their outstanding shares is at $464.3 million.
    • Grifols (NASDAQ:GRFS) stock declined by 9.15% to $5.76. The market value of their outstanding shares is at $3.9 billion.
    • Qilian Intl Hldg Gr (NASDAQ:QLI) shares decreased by 8.97% to $0.59. The company's market cap stands at $21.1 million.
    • Biophytis (NASDAQ:BPTS) stock fell 8.39% to $0.45. The company's market cap stands at $4.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ANNX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANNX
    $APM
    $BGXX
    $BPTS

    CompanyDatePrice TargetRatingAnalyst
    Spruce Biosciences Inc.
    $SPRB
    12/23/2025$283.00Outperform
    Oppenheimer
    Annexon Inc.
    $ANNX
    12/23/2025$16.00Buy
    Chardan Capital Markets
    Spruce Biosciences Inc.
    $SPRB
    12/3/2025$160.00Market Perform → Outperform
    Leerink Partners
    Nuvation Bio Inc.
    $NUVB
    11/24/2025Buy
    Truist
    Nuvation Bio Inc.
    $NUVB
    11/19/2025$12.00Buy
    B. Riley Securities
    Spruce Biosciences Inc.
    $SPRB
    10/28/2025$254.00Mkt Perform → Mkt Outperform
    Citizens JMP
    Nuvation Bio Inc.
    $NUVB
    9/30/2025$10.00Buy
    Jefferies
    Nuvation Bio Inc.
    $NUVB
    4/23/2025$6.00Mkt Outperform
    Citizens JMP
    More analyst ratings

    $ANNX
    $APM
    $BGXX
    $BPTS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nuvation Bio to Participate in Upcoming Investor Conferences

    NEW YORK, Feb. 25, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in four upcoming investor conferences, including fireside chats at two conferences. The management team will participate in fireside chats and one-on-one meetings at the following conferences:TD Cowen 46th Annual Health Care Confer

    2/25/26 4:05:00 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care Conference

    BRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., president and chief executive officer, will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026 at 9:50 a.m. ET. A live webcast of the event can be accessed under the ‘Events & Presentations' section on the Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation. About Annexon

    2/24/26 8:00:00 AM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

    Based on FDA Feedback, Company Continues to Advance BLA Submission for TA-ERT Using CSF HS-NRE as Reasonably Likely Surrogate Endpoint for Accelerated Approval BLA Submission for TA-ERT is Now Anticipated in the Fourth Quarter to Accommodate Drug Product PPQ Requirement Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the successful completion of Type B meetings with the U.S. Food and Drug Administration (FDA or the Agency) regarding its planned upcoming biologics license application (BLA) submission for tralesinidase alf

    2/18/26 7:00:00 AM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANNX
    $APM
    $BGXX
    $BPTS
    SEC Filings

    View All

    SEC Form 6-K filed by Grifols S.A.

    6-K - Grifols SA (0001438569) (Filer)

    2/26/26 4:25:07 PM ET
    $GRFS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Grifols S.A.

    6-K - Grifols SA (0001438569) (Filer)

    2/26/26 2:48:42 PM ET
    $GRFS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Spruce Biosciences Inc.

    SCHEDULE 13G - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)

    2/24/26 4:47:27 PM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANNX
    $APM
    $BGXX
    $BPTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by PRESIDENT AND CEO Love Douglas

    4 - Annexon, Inc. (0001528115) (Issuer)

    2/23/26 7:11:22 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF MEDICAL OFFICER Dananberg Jamie was granted 56,250 shares, increasing direct ownership by 77% to 129,402 units (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    2/23/26 7:09:58 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & CHIEF BUSINESS OFFICER Overdorf Michael was granted 62,500 shares, increasing direct ownership by 50% to 186,964 units (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    2/23/26 7:08:42 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANNX
    $APM
    $BGXX
    $BPTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer initiated coverage on Spruce Biosciences with a new price target

    Oppenheimer initiated coverage of Spruce Biosciences with a rating of Outperform and set a new price target of $283.00

    12/23/25 8:47:57 AM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital Markets initiated coverage on Annexon with a new price target

    Chardan Capital Markets initiated coverage of Annexon with a rating of Buy and set a new price target of $16.00

    12/23/25 8:41:58 AM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Spruce Biosciences upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Spruce Biosciences from Market Perform to Outperform and set a new price target of $160.00

    12/3/25 8:26:32 AM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANNX
    $APM
    $BGXX
    $BPTS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Carson William H. bought $20,657 worth of shares (4,115 units at $5.02), increasing direct ownership by 8% to 54,405 units (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    1/2/26 4:30:06 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Carson William H. bought $18,394 worth of shares (4,115 units at $4.47), increasing direct ownership by 9% to 50,290 units (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    12/3/25 4:30:14 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Choi Jung bought $138,270 worth of shares (33,000 units at $4.19) (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    12/3/25 4:30:20 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANNX
    $APM
    $BGXX
    $BPTS
    Leadership Updates

    Live Leadership Updates

    View All

    Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors

    Keli Walbert brings decades of commercial leadership experience and a proven track record of successful product launches in rare disease Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Keli Walbert to the Company's Board of Directors. "Keli joins the Board of Directors at a pivotal time as we prepare for a Biologics License Application for TA-ERT for the treatment of Sanfilippo Syndrome Type B (MPS IIIB)," said Michael Grey, Executive Chairman of Spruce Biosciences. "Her experience in successfully launch

    12/15/25 8:00:00 AM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors

    Fort Lee, NJ, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the appointment of Juan Sanchez, MD, to its Board of Directors. Dr. Sanchez is a seasoned biotech executive with expertise in industry, capital markets and medicine, having most recently served as Vice President of Corporate Communications and Investor Relations at Intra-Cellular Therapies, acquired by Johnson & Johnson in April 2025 for $14.6 billion. Ron Bentsur, Chairman and Chief Executive Officer of Nuvec

    9/25/25 8:00:00 AM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

    Tanruprubart (formerly ANX005) for GBS Advancing Through Regulatory Interactions; MAA Submission in Europe Anticipated in First Quarter of 2026; Ongoing Discussions with FDA Regarding Generalizability Package to Support a BLA Accelerated Completion of Enrollment for Global Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry AMD with GA; Selected for EMA PRIME Product Development Candidate Pilot; Topline ARCHER II Data Expected in Second Half of 2026 ANX1502 First-in-Kind Oral C1s Inhibitor Exposure Exceeded Target Concentration in Fasted Patients; Evaluation in Relation to Food Intake Ongoing in Proof-of-Concept CAD Study, Update Expected by Year-end 2025 $227 Million i

    8/14/25 4:05:00 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANNX
    $APM
    $BGXX
    $BPTS
    Financials

    Live finance-specific insights

    View All

    Nuvation Bio to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 2, 2026

    NEW YORK, Feb. 17, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Monday, March 2, 2026, at 4:30 p.m. ET to discuss its financial results and business updates for the fourth quarter and full year of 2025. Investors and the general public are invited to listen to the live webcast and may register on the Investor Relations section of the Nuvation Bio website. To access the live conference call, participants can dial +

    2/17/26 4:05:00 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration

    CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 18, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that through its wholly-owned subsidiary, it has exercised its warrant to acquire the common stock in Spruce Biosciences, Inc. (NASDAQ:SPRB) ("Spruce"). Following this transaction, Harbour BioMed holds approximately 3.8% of the total outstanding shares of Spruce and approximately 3.1% of the fully diluted shares of Spruce[1].

    1/18/26 7:02:00 PM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

    -   Remain on track to resubmit the New Drug Application (NDA) for oxylanthanum carbonate (OLC) by year end -   Presented new analysis of OLC data at American Society of Nephrology (ASN) which demonstrates that OLC significantly reduced pill burden in terms of both pill volume (7x) and pill count (2x) compared to currently available phosphate binders -   Ended Q3 with $42.7 million of cash with expected runway into 2027 LOS ALTOS, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for t

    11/12/25 7:05:00 AM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANNX
    $APM
    $BGXX
    $BPTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Annexon Inc.

    SC 13G/A - Annexon, Inc. (0001528115) (Subject)

    11/14/24 7:21:59 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Unicycive Therapeutics Inc.

    SC 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)

    11/14/24 7:13:38 PM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Unicycive Therapeutics Inc.

    SC 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)

    11/14/24 7:01:14 PM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care